{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:07:25Z","timestamp":1790384845625,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.urolonc.2016.05.028","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T22:42:26Z","timestamp":1467240146000},"page":"460-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Follow-up in non\u2013muscle-invasive bladder cancer\u2014International Bladder Cancer Network recommendations"],"prefix":"10.1016","volume":"34","author":[{"given":"Wassim","family":"Kassouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer L.","family":"Traboulsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Schmitz-Dr\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert Barton","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus A.","family":"Kiemeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goebell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.05.028_bib1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib3","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)65168-3","article-title":"Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression","volume":"167","author":"Holmang","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","article-title":"Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients","volume":"33","author":"Martin-Doyle","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib5","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/j.juro.2009.08.083","article-title":"Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer","volume":"182","author":"Cho","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.05.028_bib8","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.4081\/rt.2011.e22","article-title":"Is radical cystectomy mandatory in every patient with variant histology of bladder cancer","volume":"3","author":"Shapur","year":"2011","journal-title":"Rare Tumors"},{"key":"10.1016\/j.urolonc.2016.05.028_bib9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.ju.0000169424.79702.6d","article-title":"Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor","volume":"174","author":"Palou","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0090-4295(96)00571-7","article-title":"Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management","volume":"49","author":"Solsona","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.05.028_bib11","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0022-5347(05)67137-6","article-title":"Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups","volume":"164","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14040","article-title":"Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer","volume":"14","author":"Mowatt","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.urolonc.2016.05.028_bib13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.eururo.2009.09.037","article-title":"Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy","volume":"57","author":"Draga","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1464-410X.2009.08839.x","article-title":"Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin","volume":"105","author":"Ray","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.05.028_bib16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.eururo.2012.01.018","article-title":"A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence","volume":"61","author":"Naselli","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib17","doi-asserted-by":"crossref","first-page":"E680","DOI":"10.1111\/j.1464-410X.2012.11500.x","article-title":"Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis","volume":"110","author":"Zheng","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.05.028_bib18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejrad.2008.10.026","article-title":"Performance of computed tomographic urography in diagnosis of upper urinary tract urothelial carcinoma, in patients presenting with hematuria: systematic review and meta-analysis","volume":"73","author":"Chlapoutakis","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.juro.2013.05.020","article-title":"Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer","volume":"190","author":"Sternberg","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib20","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.juro.2009.12.031","article-title":"Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy","volume":"183","author":"Takahashi","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib21","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1046\/j.1464-410x.2000.00973.x","article-title":"Magnetic resonance urography enhanced by gadolinium and diuretics: a comparison with conventional urography in diagnosing the cause of ureteric obstruction","volume":"86","author":"Jung","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.05.028_bib22","series-title":"The pathology of bladder cancer","first-page":"91","article-title":"Cytology of bladder cancer","author":"King","year":"1983"},{"key":"10.1016\/j.urolonc.2016.05.028_bib23","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/S0022-5347(05)67104-2","article-title":"A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma","volume":"164","author":"Halling","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0090-4295(02)02136-2","article-title":"Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses","volume":"61","author":"Lotan","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.05.028_bib25","doi-asserted-by":"crossref","first-page":"27.e1","DOI":"10.1016\/j.urolonc.2012.09.011","article-title":"Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer","volume":"32","author":"Yafi","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.eururo.2005.03.014","article-title":"Urine markers for bladder cancer surveillance: a systematic review","volume":"47","author":"van Rhijn","year":"2005","journal-title":"Eur Urol"},{"issue":"Suppl. 8","key":"10.1016\/j.urolonc.2016.05.028_bib27","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eursup.2009.06.008","article-title":"Cytology and urinary markers for the diagnosis of bladder cancer","volume":"2009","author":"van Rhijn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.urology.2006.01.034","article-title":"Urothelial cancer biomarkers for detection and surveillance","volume":"67","author":"Liou","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.05.028_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000369357","article-title":"Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO\/ICUD consensus","volume":"94","author":"Schmitz-Dr\u00e4ger","year":"2015","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2016.05.028_bib30","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/1097-0142(20010815)92:4<768::AID-CNCR1381>3.0.CO;2-C","article-title":"Microsatellite analysis\u2014DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial","volume":"92","author":"van Rhijn","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2016.05.028_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00005392-200102000-00005","article-title":"Human complement factor H related protein test for monitoring bladder cancer","volume":"165","author":"Raitanen","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.295.3.299","article-title":"Surveillance for recurrent bladder cancer using a point-of-care proteomic assay","volume":"295","author":"Grossman","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.urolonc.2016.05.028_bib33","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.urology.2008.04.051","article-title":"Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder","volume":"73","author":"Gupta","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.05.028_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/modpathol.3800262","article-title":"ImmunoCyt\/uCyt+improves the sensitivity of urine cytology in patients followed for urothelial carcinoma","volume":"18","author":"Tetu","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cncr.21712","article-title":"uCyt+\/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses","volume":"108","author":"Mian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2016.05.028_bib36","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.eururo.2006.10.044","article-title":"UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer","volume":"51","author":"Moonen","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2008.05.001","volume":"55","author":"van der Aa","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.juro.2009.08.150","article-title":"Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial","volume":"183","author":"van der Aa","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.urolonc.2007.06.002","article-title":"UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing","volume":"26","author":"Hajdinjak","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib40","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1464-410X.2010.10026.x","article-title":"Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity","volume":"108","author":"Kamat","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.05.028_bib41","doi-asserted-by":"crossref","first-page":"973406","DOI":"10.1155\/2014\/973406","article-title":"Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer","volume":"2014","author":"Todenhofer","year":"2014","journal-title":"Dis Markers"},{"key":"10.1016\/j.urolonc.2016.05.028_bib42","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jama.293.7.810","article-title":"Detection of bladder cancer using a point-of-care proteomic assay","volume":"293","author":"Grossman","year":"2005","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.urolonc.2016.05.028_bib43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.ju.0000149825.83180.a4","article-title":"Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization","volume":"173","author":"Kipp","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib44","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.juro.2011.10.144","article-title":"Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial","volume":"187","author":"Kamat","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1309\/ADJL7E810U1H42BJ","article-title":"Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings","volume":"127","author":"Yoder","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib46","unstructured":"Babjuk M, B\u00f6hle A, Burger M, et al: EAU: Guidelines on Non-Muscle Invasive Bladder Cancer (Ta, T1 and CIS): Update 2015. Available at http:\/\/uroweb.org [accessed 05.08.15]."},{"key":"10.1016\/j.urolonc.2016.05.028_bib47","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib48","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. V.1.2014. Available at http:\/\/www.nccn.org [accessed on 15.06.15]."},{"key":"10.1016\/j.urolonc.2016.05.028_bib49","doi-asserted-by":"crossref","first-page":"E690","DOI":"10.5489\/cuaj.3320","article-title":"CUA guidelines on the management of non-muscle invasive bladder cancer","volume":"9","author":"Kassouf","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2016.05.028_bib50","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2011.11.011","article-title":"Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years?","volume":"61","author":"Holmang","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib53","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1464-410X.2010.09899.x","article-title":"Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma","volume":"108","author":"Messer","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.05.028_bib54","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1464-410X.2008.08032.x","article-title":"Positive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy?","volume":"103","author":"Karl","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.05.028_bib55","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","article-title":"Expectant management of small, recurrent, noninvasive papillary bladder tumors","volume":"170","author":"Soloway","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib56","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.juro.2007.05.148","article-title":"Management of low grade papillary bladder tumors","volume":"178","author":"Herr","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib57","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.urolonc.2015.04.018","article-title":"Comparison of outcomes between ultrasonography and cystoscopy in the surveillance of patients with initially diagnosed TaG1-2 bladder cancers: A matched-pair analysis","volume":"33","author":"Niwa","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib58","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/01.ju.0000149163.08521.69","article-title":"A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database","volume":"173","author":"Mariappan","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib59","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.05.028_bib60","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cncy.21272","article-title":"Cytologic and cystoscopic predictors of recurrence and progression in patients with low-grade urothelial carcinoma","volume":"121","author":"Jackson","year":"2013","journal-title":"Cancer Cytopathol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916301090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916301090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:09:24Z","timestamp":1761041364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143916301090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1078143916301090"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.05.028","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follow-up in non\u2013muscle-invasive bladder cancer\u2014International Bladder Cancer Network recommendations","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}